J Curtis Nickel1, Stephen J Freedland2, Ramiro Castro-Santamaria2, Daniel M Moreira2. 1. Department of Urology, Queen's University, Kingston, Ontario, Canada; Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California; Global R&D, GlaxoSmithKline Inc., King of Prussia, Pennsylvania; Department of Urology, University of Illinois at Chicago, Chicago, Illinois. Electronic address: jcn@queensu.ca. 2. Department of Urology, Queen's University, Kingston, Ontario, Canada; Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California; Global R&D, GlaxoSmithKline Inc., King of Prussia, Pennsylvania; Department of Urology, University of Illinois at Chicago, Chicago, Illinois.
Abstract
PURPOSE: We examined the 4-year longitudinal association between histological prostate inflammation and chronic prostatitis/chronic pelvic pain syndrome. We also studied the development of new and progressing existing chronic prostatitis/chronic pelvic pain syndrome in men randomized to placebo in the REDUCE (REduction by DUtasteride of prostate Cancer Events) population. MATERIALS AND METHODS: At multiple time points during 4 years univariable and multivariable analyses were performed between acute and chronic inflammation detected on baseline biopsies and the incidence of chronic pelvic pain syndrome-like symptoms, defined as a positive response to CPSI (Chronic Prostatitis Symptom Index) question 1a-perineal pain and/or question 2b-ejaculatory pain and a total pain subscore of at least 4, and progression of chronic prostatitis/chronic pelvic pain syndrome, defined as a 4-point or greater increase from baseline in total CPSI score, in patients with a baseline categorization of chronic prostatitis/chronic pelvic pain syndrome. RESULTS: Of the 4,109 men in the study acute and chronic inflammation was detected in 641 (15.6%) and 3,216 (78.3%), respectively. Chronic prostatitis/chronic pelvic pain syndrome symptom status was available for 2,816 at baseline. Chronic prostatitis/chronic pelvic pain syndrome-like symptoms developed in 317 of 2,150 men without the condition at baseline who had followup data. Acute and chronic inflammation was not associated with the incidence of the symptoms (p >0.1). At a median followup of 12.0 months 109 of 145 men with baseline chronic prostatitis/chronic pelvic pain syndrome and followup data showed symptomatic progression. Chronic but not acute inflammation was significantly associated with shorter time to progression on univariable and multivariable analyses (p = 0.029 and 0.018, respectively). CONCLUSIONS: Inflammation is not associated with an increased risk of chronic prostatitis/chronic pelvic pain syndrome. However, chronic inflammation predicts the risk of symptomatic progression in men in whom chronic prostatitis/chronic pelvic pain syndrome symptoms have been identified.
RCT Entities:
PURPOSE: We examined the 4-year longitudinal association between histological prostate inflammation and chronic prostatitis/chronic pelvic pain syndrome. We also studied the development of new and progressing existing chronic prostatitis/chronic pelvic pain syndrome in men randomized to placebo in the REDUCE (REduction by DUtasteride of prostate Cancer Events) population. MATERIALS AND METHODS: At multiple time points during 4 years univariable and multivariable analyses were performed between acute and chronic inflammation detected on baseline biopsies and the incidence of chronic pelvic pain syndrome-like symptoms, defined as a positive response to CPSI (Chronic Prostatitis Symptom Index) question 1a-perineal pain and/or question 2b-ejaculatory pain and a total pain subscore of at least 4, and progression of chronic prostatitis/chronic pelvic pain syndrome, defined as a 4-point or greater increase from baseline in total CPSI score, in patients with a baseline categorization of chronic prostatitis/chronic pelvic pain syndrome. RESULTS: Of the 4,109 men in the study acute and chronic inflammation was detected in 641 (15.6%) and 3,216 (78.3%), respectively. Chronic prostatitis/chronic pelvic pain syndrome symptom status was available for 2,816 at baseline. Chronic prostatitis/chronic pelvic pain syndrome-like symptoms developed in 317 of 2,150 men without the condition at baseline who had followup data. Acute and chronic inflammation was not associated with the incidence of the symptoms (p >0.1). At a median followup of 12.0 months 109 of 145 men with baseline chronic prostatitis/chronic pelvic pain syndrome and followup data showed symptomatic progression. Chronic but not acute inflammation was significantly associated with shorter time to progression on univariable and multivariable analyses (p = 0.029 and 0.018, respectively). CONCLUSIONS:Inflammation is not associated with an increased risk of chronic prostatitis/chronic pelvic pain syndrome. However, chronic inflammation predicts the risk of symptomatic progression in men in whom chronic prostatitis/chronic pelvic pain syndrome symptoms have been identified.
Authors: Emma H Allott; Sarah C Markt; Lauren E Howard; Adriana C Vidal; Daniel M Moreira; Ramiro Castro-Santamaria; Gerald L Andriole; Lorelei A Mucci; Stephen J Freedland Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-04-18 Impact factor: 4.254
Authors: Marianna Gasperi; John N Krieger; Matthew S Panizzon; Jack Goldberg; Dedra Buchwald; Niloofar Afari Journal: Urology Date: 2019-04-13 Impact factor: 2.649
Authors: Ling Hao; Yatao Shi; Samuel Thomas; Chad M Vezina; Sagar Bajpai; Arya Ashok; Charles J Bieberich; William A Ricke; Lingjun Li Journal: Int J Mass Spectrom Date: 2018-09-22 Impact factor: 1.986
Authors: Ling Hao; Samuel Thomas; Tyler Greer; Chad M Vezina; Sagar Bajpai; Arya Ashok; Angelo M De Marzo; Charles J Bieberich; Lingjun Li; William A Ricke Journal: Am J Physiol Renal Physiol Date: 2019-04-17
Authors: Marianna Gasperi; John N Krieger; Christopher Forsberg; Jack Goldberg; Dedra Buchwald; Niloofar Afari Journal: J Psychosom Res Date: 2017-09-06 Impact factor: 3.006